Abstract:The global prevalence of type 2 diabetes mellitus (DM2) has been rising significantly over the years. Recent studies have shown beneficial effects of cinnamon on metabolic biomarkers. The objective of this review was to assess the effect of cinnamon supplementation on metabolic biomarkers in patients with DM2. The Pubmed/MEDLINE, Cochrane CENTRAL, and Embase databases were searched up to November 10, 2022. A systematic search was performed for randomized controlled trials (RCTs) evaluating the effect of cinnamon supplementation on metabolic biomarkers, in adults and the elderly with DM2, and comparing the data for a cinnamon intervention group with that for a placebo group or a control group. The main exclusion criteria were studies (1) with other types of diabetes (ie, gestational diabetes or type 1 diabetes), (2) without cinnamon consumption, (3) that did not evaluate metabolic biomarkers, or (4) in vitro and animal studies. Two researchers independently screened 924 records, evaluated full-text studies, extracted data, and appraised their quality. A third researcher was consulted to resolve any discrepancies. The data were pooled using random-effects models and expressed as the weighted mean difference (WMD) with 95% CI. Heterogeneity was assessed using Cochran's Q test and quantified using I 2 statistics. Risk of bias was assessed using the Joanna Briggs Institute (JBI) instrument. Sensitivity analysis and the GRADE system were used to assess the robustness and certainty of the findings. In total, 28 RCTs with a duration ranging from 30 to 120 days and a total enrollment of 3054 patients with DM2 were included. Participants consuming cinnamon showed a significant reduction in fasting blood glucose (FBG) (WMD: −15.26 mg/dL; 95% CI: −22.23 to −8.30; I 2 = 88%), postprandial glucose (WMD: −39.22 mg/dL; 95% CI: −63.90 to −14.55; I 2 = 100%), HbA1c (WMD: −0.56 mg/dL; 95% CI: −0.99 to −0.13; I 2 = 94%), and HOMA-IR (WMD = −0.76, 95% CI: −1.13 to −0.39; I 2 = 22%) compared with the control group. An intervention of cinnamon in capsule form reduced FBG (WMD:−18.43 mg/dL, 95% CI: −26.32 to −10.53; I 2 = 89%), postprandial glucose (WMD: −44.83 mg/dL, 95% CI: −70.67 to −18.99; I 2 = 100%), HbA1c (WMD: −0.56 mg/dL, 95% CI: −1.02 to −0.09; I 2 = 94%), total cholesterol (WMD: −13.39 mg/dL; 95% CI: −24.71 to −2.07; I 2 = 96%), LDL-C (WMD: −6.49 mg/dL, 95% CI: −12.69 to −0.29; I 2 = 92%), and triglycerides (WND: −19.75 mg/dL; 95% CI, −33.71 to −5.80; I 2 = 88%). Both doses (≤2 g/day and >2 g/day) reduced FBG and postprandial glucose. Only cinnamon doses of ≤2 g/day reduced HbA1c (WMD: −0.68 mg/dL, 95% CI: −1.16 to −0.1; I 2 = 92%), HOMA-IR (WMD: −0.94 mg/dL; 95% CI: −1.21 to −0.67; I 2 = 0%), and BMI (WMD: −1.18 kg/m 2 ; 95% CI: −1.97 to −0.39; I 2 = 0%). The data suggest that cinnamon improves the glycemic and lipid profile and reduces the BMI, particularly in DM2 patients who receive cinnamon supplementation in capsule form and at a dose of ≤2 g/day. PROSPERO registration no. CRD42022370332.

Effect of cinnamon supplementation on blood pressure, oxidative stress, and inflammatory biomarkers in adults: An umbrella review of the meta-analyses of randomized controlled trials

Efficacy of cinnamon supplementation on glycolipid metabolism in T2DM diabetes: A meta-analysis and systematic review

Safety of Cinnamon: An Umbrella Review of Meta-Analyses and Systematic Reviews of Randomized Clinical Trials

The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes mellitus: An updated systematic review and dose‐response meta‐analysis of randomized controlled trials

Effect of cinnamon as a Chinese herbal medicine on markers of cardiovascular risk in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials

Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: a systematic review and meta-analysis

The effect of curcumin supplementation on endothelial function and blood pressure in patients with metabolic disorders: A meta-analysis of meta-analyses

The Effect of Cinnamon on Glycolipid Metabolism: A Dose–Response Meta-Analysis of Randomized Controlled Trials

Cinnamon, an effective anti-obesity agent: Evidence from an umbrella meta-analysis.

Effects of Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and Antioxidant Status in Type 2 Diabetic Patients

Efficacy of Ginger, Cardamom, Purslane, Saffron and Cinnamon Consumption on Lipid Profile, Glycemic Control, Blood Pressure and Markers of Anthropometric and Inflammation in Metabolic Syndrome Patients: A Systematic Review and Network Meta-Analysis

Effect of cinnamon spice on continuously monitored glycemic response in adults with prediabetes: a 4-week randomized controlled crossover trial

A Systematic Review Evaluating Cinnamon's Effects on Glucose Utilizing a Ranking System to Assess Bias and Study Quality

Cinnamon Could Improve Hepatic Steatosis Caused by a High-Fat Diet Via Enhancing Hepatic Beta-Oxidation and Inhibiting Hepatic Lipogenesis, Oxidative Damage, and Inflammation in Male Rats

Cinnamon As Dietary Supplement Caused Hyperlipidemia in Healthy Rats.

The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials

Antioxidant Effects of a Cinnamon Extract in People with Impaired Fasting Glucose That Are Overweight or Obese

The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance

Mechanistic and therapeutic insight into the effects of cinnamon in polycystic ovary syndrome: a systematic review

Cinnamon for diabetes mellitus

Evaluation of therapeutic effects of aqueous cinnamon extract against obesity associated dysregulation of pituitary-adrenal axis